advertisement

Topcon

Abstract #95116 Published in IGR 22-2

Loss of P2Y receptors triggers glaucoma-like pathology in mice

Hamada K; Shinozaki Y; Namekata K; Matsumoto M; Ohno N; Segawa T; Kashiwagi K; Harada T; Koizumi S
British Journal of Pharmacology 2021; 0:


BACKGROUND AND PURPOSE: Glaucoma, the leading cause of blindness, damages the retinal ganglion cells. Elevated intraocular pressure (IOP) is a high-risk factor for glaucoma, so topical hypotensive drugs are usually used for treatment. Because not all patients do not respond adequately to current treatments, there is a need to identify a new molecular target to reduce IOP. Here, we have assessed the role of P2Y1 receptors in mediating elevated IOP. EXPERIMENTAL APPROACH: P2Y receptor agonist was instilled into the eyes of mice, and the IOP changes were measured by a rebound-type tonometer. Expression of P2Y receptors was estimated by immunohistochemistry. Ocular function was measured by a multifocal electroretinogram. KEY RESULTS: A single dose of the P2Y receptor agonist transiently reduced IOP and such effects were absent in P2Y receptor-deficient (P2Y KO) mice. P2Y receptors were functionally expressed in the ciliary body, trabecular meshwork and Schlemm's canal. Activation of P2Y receptors negatively regulated aquaporin 4 (AQP4) function but up-regulated endothelial NOS (eNOS). P2Y KO mice showed chronic ocular hypertension regardless of age. P2Y KO mice at 3 months old showed no damage to retinal ganglion cells, whereas 12-month-old mice showed a significant loss of these cells and impairment of ocular functions. Damage to retinal ganglion cells was attenuated by chronic administration of an IOP-reducing agent. CONCLUSION AND IMPLICATIONS: Activation of P2Y receptors reduced IOP via dual pathways including AQP4 and eNOS. Loss of P2Y receptors resulted in glaucomatous optic neuropathy, suggesting that P2Y receptors might provide an effective target in the treatment of glaucoma.

Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.

Full article

Classification:



Issue 22-2

Change Issue


advertisement

Oculus